Skip to content
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Corporate Presentation
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Press Releases
Contact Us
Menu
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Corporate Presentation
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Press Releases
Contact Us
SVB Securities Global Biopharma Conference
February 16, 2023
8:00 am
Publications
Click here for Webcast
READ MORE
March 14, 2024
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Read More »
November 14, 2023
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
Read More »
September 12, 2023
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
Read More »
See all News
Thank You
Message Sent!
We will get back to you soon